June 25, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Trodelvy earns FDA approval as first-line treatment for triple-negative breast cancer
The FDA has approved sacituzumab govitecan-hziy as first-line therapy for adults with unresectable locally advanced or metastatic triple-negative breast cancer across PD-L1 status. Sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences) — a TROP2-directed antibody-drug conjugate — received approval as a single agent for patients who are not eligible for PD-1 or PD-L1 inhibitors, and in
731 words~3 min read
